ORGS - オ―ジェネシス (Orgenesis Inc.)

ORGSのニュース

   Why Orgenesis Stock Is Getting Hammered Thursday  2023/02/23 17:11:32 Benzinga
Orgenesis Inc (NASDAQ: ORGS ) shares are trading lower by 29.95% to $1.45 Thursday morning after the company announced pricing of a $3.7 million registered direct offering. What Else? Orgenesis today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale … Full story available on Benzinga.com
   Orgenesis stock sinks ~31% after launching offering to raise $3.7M (NASDAQ:ORGS)  2023/02/23 16:57:41 Seeking Alpha
Shares of biotech company Orgenesis (ORGS) slumped nearly 31% to a daily low of $1.43 on Thursday after announcing stock and warrants offering to raise $3.7 million.
   Orgenesis Announces Pricing of $3.7 Million Registered Direct Offering of Common Stock, Warrants  2023/02/23 14:59:04 Investing.com
https://www.investing.com/news/assorted/orgenesis-announces-pricing-of-37-million-registered-direct-offering-of-common-stock-warrants-432SI-3012536
   Orgenesis''s Return On Capital Employed Insights  2022/12/22 14:46:56 Benzinga
According to data from Benzinga Pro, during Q3, Orgenesis ''s (NASDAQ: ORGS ) reported sales totaled $7.84 million. Despite a 74.36% increase in earnings, the company posted a loss of $1.41 million. In Q2, Orgenesis brought in $7.20 million in sales but lost $5.49 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
   Orgenesis PT Lowered to $6 at Benchmark  2022/11/23 12:22:01 Investing.com
https://www.investing.com/news/pro/orgenesis-pt-lowered-to-6-at-benchmark-432SI-2950745
   Orgenesis''s Return On Capital Employed Insights  2022/12/22 14:46:56 Benzinga
According to data from Benzinga Pro, during Q3, Orgenesis ''s (NASDAQ: ORGS ) reported sales totaled $7.84 million. Despite a 74.36% increase in earnings, the company posted a loss of $1.41 million. In Q2, Orgenesis brought in $7.20 million in sales but lost $5.49 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
   Orgenesis PT Lowered to $6 at Benchmark  2022/11/23 12:22:01 Investing.com
https://www.investing.com/news/pro/orgenesis-pt-lowered-to-6-at-benchmark-432SI-2950745
   Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday  2022/11/14 07:35:17 Benzinga
Gainers ShiftPixy, Inc. (NASDAQ: PIXY ) shares surged 56.6% to settle at $19.10 on Friday. Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed policy after CPI this week showed October inflation below estimates. Exela Technologies, Inc. (NASDAQ: XELA ) gained 50.3% to close at $0.2780. The company is expected to report Q3 results on November 14, 2022. uCloudlink Group Inc. (NASDAQ: UCL ) jumped 49.6% to close at $1.90. uCloudlink Group is expected to report Q3 financial results on November 16, 2022. Core Scientific, Inc. (NASDAQ: CORZ ) gained 44.3% to settle at $0.1981. Compass, Inc. (NYSE: COMP ) jumped 44% to close at $3.50. Compass posted a wider-than-expected loss for its third quarter, while sales topped estimates. Kaleyra, Inc. (NYSE: KLR ) climbed 38.5% to close at $0.90. Kaleyra extended Oracle partnership to leverage Oracle Cloud. Nutex Health Inc. (NASDAQ: NUTX ) gained 37.7% to close at $1.16. MiNK Therapeutics, Inc. (NASDAQ: INKT ) jumped 35.8% to close at $3.00.
   Orgenesis (ORGS) Q3 2022 Earnings Call Transcript  2022/11/14 02:29:02 Seeking Alpha
Orgenesis (NASDAQ:NASDAQ:ORGS) Q3 2022 Earnings Conference Call November 11, 2022 08:00 ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer…
   Orgenesis GAAP EPS of $0.05  2022/11/10 22:56:05 Seeking Alpha
Orgenesis press release (ORGS): Q3 GAAP EPS of $0.05.Cash and cash equivalents of $3.01M
   Volume - Orgenesis Inc. Short Interest Up 52.4% in May  2022/06/14 21:41:09 Business Mag
Orgenesis Inc. saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 215,400 shares, an increase of 52.4% from the May 15th…
   Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials, Assesses DelveInsight  2022/05/18 17:00:00 Benzinga
New York, USA, May 18, 2022 (GLOBE NEWSWIRE) -- Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials, Assesses DelveInsight Oncolytic Virus Cancer Therapy Pipeline involves 70+ key companies continuously working towards developing 100+ Oncolytic Virus Cancer therapies, as per DelveInsight DelveInsight''s '' Oncolytic Virus Cancer Therapy Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Oncolytic Virus Cancer Therapy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Oncolytic Virus Cancer Therapy pipeline domain. Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report DelveInsight''s Oncolytic Virus Cancer Therapy Pipeline report depicts a robust space with 70+ active players working to develop 100+ pipeline therapies for Oncolytic Viruses Cancer treatment. Leading Oncolytic Virus Cancer Therapy companies such as Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Oncolys Biopharma, Replimune, Transgene, Sorrento Therapeutics, ORCA Therapeutics, TILT Biotherapeutics, BioEclipse Therapeutics, Oncolytics Biotech, Oncorus, DNAtrix, OncoMyx Therapeutics, Vyriad, Boehringer Ingelheim, IconOVir Bio, Imugene, Turnstone Biologics, Immvira Pharma, SillaJen Biotherapeutics, Advantagene, Nouscom, TOT Biopharm, Elicera Therapeutics, Takeda, Candel Therapeutics, Valo Therapeutics, Tessa Therapeutics, PsiOxus Therapeutics, KaliVir Immunotherapeutics, Oncos Therapeutics, Mustang Bio, Takara Bio, Vaxiion Therapeutics, Synthetic Biologics, Calidi Biotherapeutics, Genelux Corporation, Shanghai Sunway Biotech, BioInvent International AB, Guizhou Sinorda Biomedicine, EpicentRx, Hookipa Pharma Inc.
   Orgenesis to raise $14.8M in stock and warrants offering  2022/03/31 12:04:54 Seeking Alpha
Orgenesis (ORGS) entered into a definitive securities purchase agreement with certain investors for the sale of 4.9M shares in a private placement at $3/share and warrants to purchase up…
   Orgenesis'' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript  2022/03/31 02:50:23 Seeking Alpha
   Orgenesis GAAP EPS of -$0.74, revenue of $35.5M  2022/03/30 11:22:02 Seeking Alpha
Orgenesis press release (ORGS): FY GAAP EPS of -$0.74.Revenue of $35.5M (+361.0% Y/Y).

calendar